Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > :-)

<< Previous

Bullboard Posts

Next >>

Comment by GameChangerBeton Jul 13, 2021 4:49pm

153 Views

Post# 33537244

RE:RE:RE::-)

Please, don't insult my intelligence by coming accross with a suggestion of innocence, because you know exactly 100% what he's doing and what his intentions are.

Take a step back man, both of you

123ABC wrote: I didn't see anywhere in his post that he was referring to Phase 3, he's obviously refering to one of the many reasons why the SP is in the gutter.

<< Previous

Bullboard Posts

Next >>

Global Tungsten Market and Supply Security